[Infographics] 1L lorlatinib achieves longest ever PFS in ALK+ NSCLC: 5-year data from the CROWN trial
16 Aug 2024
![[Infographics] 1L lorlatinib achieves longest ever PFS in ALK+ NSCLC: 5-year data from the CROWN trial](https://prdmspst.blob.core.windows.net/images/articles/hk-pfi-842mo00-1ba26a3f-ad9e-4a40-a539-5b8900e99a1a-thumbnail.png)
American Society of Clinical Oncology (ASCO) 2024: 5-year data from the international, randomized, open-label phase III CROWN trial comparing lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small-cell lung cancer (NSCLC) demonstrate unprecedented progression-free survival (PFS) with lorlatinib.
![[Infographics] 1L lorlatinib achieves longest ever PFS in ALK+ NSCLC: 5-year data from the CROWN trial](_content/MIMS.Specialty.Components/assets/image_onerror_lg.webp)
![[Infographics] 1L lorlatinib achieves longest ever PFS in ALK+ NSCLC: 5-year data from the CROWN trial](_content/MIMS.Specialty.Components/assets/image_onerror.webp)
Resources
[Infographics] 1L lorlatinib achieves longest ever PFS in ALK+ NSCLC: 5-year data from the CROWN trial
[Infographics] 1L lorlatinib achieves longest ever PFS in ALK+ NSCLC: 5-year data from the CROWN trial